Company Profile
Discover and develop the best medicine to serve patients
View More
We are a commercial stage biopharmaceutical
company dedicated to discovering, developing and commercializing innovative
therapeutics that address unmet medical needs across viral infectious diseases,
oncology and inflammatory disorders. With a history that can be traced back
from 2018, we are founded by a seasoned leadership team with deep expertise in
biopharmaceutical R&D and successfully developed our Core Product,
sebaloxavir marboxil tablets, a next-generation oral anti influenza drug, which
has been approved by NMPA. We are actively broadening the reach of sebaloxavir
marboxil through a suspension formulation tailored for the pediatric population
and indication expansion into post-exposure prophylaxis.
